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Abstract Carbohydrate-deficient glycoprotein (CDG) syn- 
dromes are genetic multisystemic disorders characterized by de- 
fective N-glycosylation of serum and cellular proteins. The activ- 
ity of pbosphomannomutase was markedly deficient (-< 10% of 
the control activity) in fibroblasts, liver and/or leucocytes of 6 
patients with CDG syndrome type I. Other enzymes involved in 
the conversion of glucose to mannose l-phosphate, as well as 
phosphoglucomutase, had normal activities. Phosphomannomu- 
tase activity was normal in fibroblasts of 2 patients with CDG 
syndrome type II. Since this enzyme provides the mannose 1- 
phosphate required for the initial steps of protein glycosylation, 
it is concluded that phosphomannomutase d ficiency, which is 
first reported here for higher organisms, is a cause, and most 
likely the major one, of CDG syndrome type I. 
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1. Introduction 
Carbohydrate-deficient glycoprotein (CDG) syndromes are 
a family of multisystemic genetic diseases in which secretory 
glycoproteins, lysosomal enzymes and probably also mem- 
brane proteins are underglycosylated. Since its first report in 
1980 [1], > 100 patients have been identified [2]. Three clinical 
variants have been described, of which type I is by far the most 
frequent. Type II is due to a deficiency in N-acetylglucosam- 
inyltransferase If, a Golgi enzyme, and is therefore a defect in 
the late stages of glycosylation [3~,]. The basic defect in type 
I is still unknown; the fact that the structure of the N-linked 
oligosaccharides on transferrin is normal but that their total 
number is decreased points to a disturbance in the early steps 
of glycosylation, possibly in the formation of the dolichol- 
pyrophosphate oligosaccharide precursor or in its transfer to 
the acceptor protein [5 7]. Accordingly, there is a decreased 
incorporat ion of [3H]mannose into N-linked oligosaccharides 
and in their lipid precursors in fibroblasts of patients with CDG 
syndrome type I [8]. 
In the present work, we have explored the possibility that a 
deficiency of one of the enzymes involved in the conversion of 
glucose to mannose 1-phosphate was responsible for this dis- 
ease. 
2. Materials and methods 
2.1, Materials 
Mannose 6-phosphate, mannose 1-phosphate and yeast phospho- 
mannoisomerase were from Sigma. Other auxiliary enzymes and 
NADP were from Boehringer Mannheim. Mannose 1,6-bisphosphate 
was prepared by incubating 0,3 mM mannose 1-phosphate and 0.2 mM 
glucose 1,6-bisphosphate in the presence of 50 mM Hepes pH 7.1, 5 mM 
MgCI2, 0.25 mM NADE 1 mM dithiothreitol, 5/~g/ml yeast glucose 
6-phosphate d hydrogenase, and 10/lg/ml muscle phosphoglucomutase 
for 1 h at 30°C. The reaction was followed by the change in A340 and 
arrested by heating the mixture for 5 min at 80°C. 
2.2. Preparation of cell extracts 
Fibroblasts (passage 5 to 12) were grown till confluency in Dul- 
becco's Modified Eagle's Medium supplemented with 10% calf serum. 
The dishes were washed with 150 mM NaC1 and the cells were scraped, 
pelleted by centrifugation and stored at -80°C until further use. Cell 
extracts were prepared by resuspending the cell pellet in the homogen- 
ization buffer, which contained 20 mM Hepes, 25 mM KC1, 1 mM 
dithiothreitol and 10/~g/ml each leupeptin and antipain. The suspension 
was frozen at -50°C, thawed and centrifuged at 10,000 x g for 5 min. 
The resulting extract was used for enzymatic assay and protein determi- 
nation. Liver samples were homogenized in the same buffer, using a 
glass homogenizer, and centrifuged as described above. Leucocytes 
were isolated from ~ 10 ml ofheparinized blood by the dextran procedure 
[9]. The concentration f proteins in the extracts ranged from 3 to 10 
mg protein/ml. 
2.3. Enzyme and protein assays 
All enzymes were assayed spectrophometrically t 30°C by the reduc- 
tion of NADP to NADPH, the change in A340 was measured during 60 
rain (phosphomannose i omerase, phosphomannomutase) or 10-15 
rain (other enzymes). The assay mixtures contained 50 mM Hepes pH 
7.1. 5 mM MgC12, 0.25 mM NADP and 10/~g/ml yeast glucose 6- 
phosphate dehydrogenase. Other additions were: for the hexokinase 
assay, 1 mM glucose, 1 mM ATP.Mg and 5 /11 extract; for the 
phosphoglucomutase say, 0.5 mM glucose 1-phosphate, 1 ¢tM glu- 
cose 1,6-bisphosphate nd 2 ¢*1 extract; for the phosphoglucose isom- 
erase assay, 1 mM fructose 6-phosphate and 2 HI extract; for the 
phosphomannoseisomerase assay, 0.5 mM mannose 6-phosphate, 10 
~ug/ml phosphoglucose isomerase, 2 (instead of 10)/,tg/ml glucose 6- 
phosphate dehydrogenase and 5/11 extract; for the phosphomannomu- 
tase assay, 0.1 mM mannose 1-phosphate, 1 HM mannose 1,6-bis- 
phosphate, 10 /lg/ml phosphoglucose isomerase and 3.5 ,ug/ml 
phosphomannose i omerase. All incubations were carried out with or 
without substrate, and the difference between the two values was taken 
as the enzymic activity. 1 U enzyme is the activity corresponding to the 
formation of 1 ¢tmol NADPH/min under the assay conditions. Protein 
was measured according to Bradford [10] with bovine gamma globulin 
as a standard. Results are expressed as individual values or as 
mean + SD. 
3. Results and discussion 
*Corresponding author. UCL 7539, avenue Hippocrate 75, 
B-1200 Brussels, Belgium. Fax: t32) (2) 764 7598. 
Phosphomannomutase was much less active than other en- 
zymes involved in the conversion of glucose to mannose 1- 
phosphate in control fibroblasts and ~50x less active than 
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Table 1 
Enzymic activities in fibroblasts of controls and patients with CDG syndromes types I and II 
319 
Phosphomannose i omerase Phosphomannomutase Phosphoglucomutase 
(mU/mg protein) (mU/mg protein) (mU/mg protein) 
Controls* 14.6 + 4.1 1.32 _+ 0.37 72 + 14 
CDG syndrome type l** 
HS 13.2, 10.2 <-0.1, <0.1 61, 42, 37 
PA 6.3, 10.0 ~0.1, <-0.1 66, 68 
PS 16.4. 10.0 <~01, <-0.1 41, 53, 53 
BJ 14.8. 10.5 ~ll.l, <0.1 65. 63 
CDG syndrome type I1"* 
BM 19.6, 11.4 1.4, 1.3 65, 87 
VJ 17.3, 11.7 1.9, 1.1 76, 66 
*Mean values _+ SD for l0 12 fibroblasts pellets deri~ed from 5 controls. 
**Individual values: PA and PS, the patients tirst reported [1] are homozygotic twin girls, aged 19 in 1995; HS and BJ are also girls with a typical 
CDG syndrome type I; both died around the age of 2 years. 
phosphoglucomutase (Table l). The activities of hexokinase 
(19.2 + 6.7 mU/mg protein in controls, n = 9), phosphoglucose 
isomerase (300 + 68 mU/mg protein in controls, n = 10), 
phosphomannose isomerase, and phosphoglucomutase (Table 
1) were not altered in fibroblasts from patients with CDG 
syndrome type I, in agreement with the results reported by 
Paneerselvam and Freeze [11], and in fibroblasts of 2 patients 
with CDG syndrome type II. In sharp contrast, phosphoman- 
nomutase activity was undetectable (-< 10% of the mean control 
value) in fibroblasts of 4 patients with CDG syndrome type I. 
It was normal, however, in fibroblasts of patient with CDG 
syndrome type II (Table 1), indicating that the decrease of 
activity was not the consequence of deficient glycoprotein syn- 
thesis. 
Liver biopsy specimens were available from 2 patients with 
CDG syndrome type I (BJ and HS). Phosphomannomutase 
was also deficient in this tissue, its activity being -< 0.1 mU/mg 
protein in patients as compared to 0.94 _+ 0.37 in 4 controls, 
whereas phosphoglucose isomerase, phosphomannose isom- 
erase and phosphoglucomutase were normal. To rule out the 
possibility that phosphomannomutase deficiency was due to 
the presence of an inhibitor, assays were carried out in mixtures 
of liver homogenates from patient HS and from a control. No 
inhibition of the control enzyme was observed. 
Phosphomannomutase deficiency was also found in leu- 
cocytes of 2 additional patients (female, 10 years old, named 
LA and SF) with CDG syndrome type l, the activity being 
<-0.05 mU/mg protein as compared to 0.67 + 0.29 mU/mg 
protein for 7 controls. The 3 parents of these children who were 
available for testing had an intermediate activity (-< 0.32 + 0.02 
mU/mg protein). This result indicates that phosphomannomu- 
tase deficiency is due to a mutation in the gene coding lbr this 
enzyme rather than in a regulatory gene. 
The fact that phosphomannomutase is deficient whereas 
phosphoglucomutase is normal confirms the finding that these 
two enzymes are distinct entities in mammalian tissues [12]. A 
deficiency in the former enzyme is expected to deprive the cells 
from the mannose l-phosphate and the GDP-mannose that are 
needed for the synthesis of dolichol-pyrophosphate-oligosac- 
char)des. Accordingly, mutations in the phosphomannomutasc 
gene result in defective glycosylation and in a lethal phenotype 
in yeast [13]. Our results indicate that phosphomannomutase 
deficiency is the cause of hypoglycosylation in many if not all 
patients with CDG syndrome type I. 
A linkage study in 25 European families has enabled to map 
the CDG1 gene to chromosome 16p13.3-p13.12 [14]. The au- 
thors of this work stressed that there was no evidence for 
heterogeneity among the families they tested. Since 3 cases of 
phosphomannomutase deficiency (PS, PA and HS; see Table 
1 ) were included in the study of Martinsson et al. [14], it is likely 
that the CDG1 gene mapped by these authors encodes 
phosphomannomutase. 
GDP-mannose is also required for the synthesis of other 
mannosylated conjugates, such as the glycosylphosphatidyli- 
nositol membrane anchors [15] or some O-mannosylated brain 
proteoglycans [16]. Phosphomannomutase deficiency should 
also alter these biosynthetic processes, which could explain, at 
least in part, the clinical differences between CDG syndromes 
types l and II [2]. Knowledge of the enzymatic lesion should 
now allow prenatal diagnosis and the identification of the mu- 
tations. It is worth mentioning in this respect that phosphoman- 
nomutase is expressed in amniocytes, its activity amounting to 
0.70 _+ 0.02 mU/mg protein in 3 samples. 
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